This article has been corrected to note that Brad Cole is Genomic Health's CFO and COO.

NEW YORK (GenomeWeb) – Genomic Health reported after the close of the market Tuesday that its second quarter revenues were up 11 percent year over year driven by increased sales for its Oncotype DX tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.